130 related articles for article (PubMed ID: 35323988)
21. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
[TBL] [Abstract][Full Text] [Related]
22.
George B; Kantarjian H; Baran N; Krocker JD; Rios A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639121
[TBL] [Abstract][Full Text] [Related]
23. Patterns of mutations in TP53 mutated AML.
Welch JS
Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
[TBL] [Abstract][Full Text] [Related]
24. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.
Ishizawa J; Nakamaru K; Seki T; Tazaki K; Kojima K; Chachad D; Zhao R; Heese L; Ma W; Ma MCJ; DiNardo C; Pierce S; Patel KP; Tse A; Davis RE; Rao A; Andreeff M
Cancer Res; 2018 May; 78(10):2721-2731. PubMed ID: 29490944
[TBL] [Abstract][Full Text] [Related]
25. Inflammatory cell death PANoptosis is induced by the anti-cancer curaxin CBL0137 via eliciting the assembly of ZBP1-associated PANoptosome.
Li YP; Zhou ZY; Yan L; You YP; Ke HY; Yuan T; Yang HY; Xu R; Xu LH; Ouyang DY; Zha QB; He XH
Inflamm Res; 2024 Apr; 73(4):597-617. PubMed ID: 38353723
[TBL] [Abstract][Full Text] [Related]
26. Kevetrin induces apoptosis in TP53 wild‑type and mutant acute myeloid leukemia cells.
Napolitano R; De Matteis S; Carloni S; Bruno S; Abbati G; Capelli L; Ghetti M; Bochicchio MT; Liverani C; Mercatali L; Calistri D; Cuneo A; Menon K; Musuraca G; Martinelli G; Simonetti G
Oncol Rep; 2020 Oct; 44(4):1561-1573. PubMed ID: 32945487
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin.
Wang Y; Liu Y; Bailey C; Zhang H; He M; Sun D; Zhang P; Parkin B; Baer MR; Zheng P; Malek SN; Liu Y
Oncogene; 2020 Apr; 39(14):3015-3027. PubMed ID: 32060420
[TBL] [Abstract][Full Text] [Related]
28. Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
Bories P; Prade N; Lagarde S; Cabarrou B; Largeaud L; Plenecassagnes J; Luquet I; De Mas V; Filleron T; Cassou M; Sarry A; Fornecker LM; Simand C; Bertoli S; Recher C; Delabesse E
PLoS One; 2020; 15(10):e0238795. PubMed ID: 33001991
[TBL] [Abstract][Full Text] [Related]
29. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
[TBL] [Abstract][Full Text] [Related]
30. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
Barbosa K; Li S; Adams PD; Deshpande AJ
Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
[TBL] [Abstract][Full Text] [Related]
31. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
32. Immunophenotypic dysplasia and aberrant T-cell antigen expression in acute myeloid leukaemia with complex karyotype and
Dannheim KC; Pozdnyakova O; Dal Cin P; Weinberg OK
J Clin Pathol; 2018 Dec; 71(12):1051-1059. PubMed ID: 30171088
[TBL] [Abstract][Full Text] [Related]
33. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
34. Reactivating hope for TP53-mutated acute myeloid leukaemia?
Bug G
Lancet Haematol; 2023 Apr; 10(4):e239-e240. PubMed ID: 36990618
[No Abstract] [Full Text] [Related]
35. Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cluzeau T; Loschi M; Fenaux P; Komrokji R; Sallman DA
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576266
[TBL] [Abstract][Full Text] [Related]
36. TP53 mutations in older adults with acute myeloid leukemia.
Yanada M; Yamamoto Y; Iba S; Okamoto A; Inaguma Y; Tokuda M; Morishima S; Kanie T; Mizuta S; Akatsuka Y; Okamoto M; Emi N
Int J Hematol; 2016 Apr; 103(4):429-35. PubMed ID: 26781615
[TBL] [Abstract][Full Text] [Related]
37. The TP53 Pro72Arg SNP in de novo acute myeloid leukaemia - results of two cohort studies involving 215 patients and 3759 controls.
Schulz E; Lind K; Renner W; Petersen BS; Quehenberger F; Dill C; Hofer S; Lal R; Hoefler G; Schlenke P; Ehninger G; Schetelig J; Middeke JM; Stölzel F; Sill H
Br J Haematol; 2018 Apr; 181(1):148-151. PubMed ID: 28106906
[No Abstract] [Full Text] [Related]
38. Synergistic effects of PRIMA-1
Maslah N; Salomao N; Drevon L; Verger E; Partouche N; Ly P; Aubin P; Naoui N; Schlageter MH; Bally C; Miekoutima E; Rahmé R; Lehmann-Che J; Ades L; Fenaux P; Cassinat B; Giraudier S
Haematologica; 2020 Jun; 105(6):1539-1551. PubMed ID: 31488557
[TBL] [Abstract][Full Text] [Related]
39. Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics.
Asghari H; Talati C
Curr Opin Hematol; 2020 Mar; 27(2):66-75. PubMed ID: 31922971
[TBL] [Abstract][Full Text] [Related]
40. A dominant-negative effect drives selection of
Boettcher S; Miller PG; Sharma R; McConkey M; Leventhal M; Krivtsov AV; Giacomelli AO; Wong W; Kim J; Chao S; Kurppa KJ; Yang X; Milenkowic K; Piccioni F; Root DE; Rücker FG; Flamand Y; Neuberg D; Lindsley RC; Jänne PA; Hahn WC; Jacks T; Döhner H; Armstrong SA; Ebert BL
Science; 2019 Aug; 365(6453):599-604. PubMed ID: 31395785
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
